Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Elias A T Koch - , Friedrich-Alexander-Universität Erlangen-Nürnberg (Autor:in)
  • Anne Petzold - , Friedrich-Alexander-Universität Erlangen-Nürnberg (Autor:in)
  • Anja Wessely - , Friedrich-Alexander-Universität Erlangen-Nürnberg (Autor:in)
  • Edgar Dippel - , Ludwigshafen Medical Center (Autor:in)
  • Markus Eckstein - , Universitätsklinikum der Friedrich-Alexander-Universität Erlangen-Nürnberg (Autor:in)
  • Anja Gesierich - , Universitätsklinikum Würzburg (Autor:in)
  • Ralf Gutzmer - , Ruhr-Universität Bochum (Autor:in)
  • Jessica C Hassel - , Universitätsklinikum Heidelberg (Autor:in)
  • Harald Knorr - , Friedrich-Alexander-Universität Erlangen-Nürnberg (Autor:in)
  • Nicole Kreuzberg - , Universitätsklinikum Köln (Autor:in)
  • Ulrike Leiter - , Universitätsklinikum Tübingen (Autor:in)
  • Carmen Loquai - , Universitätsmedizin Mainz (Autor:in)
  • Friedegund Meier - , Klinik und Poliklinik für Dermatologie, Hauttumorzentrum (Autor:in)
  • Peter Mohr - , Klinik und Poliklinik für Dermatologie (Autor:in)
  • Claudia Pföhler - , Universität des Saarlandes (Autor:in)
  • Farnaz Rahimi - , Klinikum der Ludwig-Maximilians-Universität (LMU) München (Autor:in)
  • Dirk Schadendorf - , Universitätsklinikum Essen (Autor:in)
  • Max Schlaak - , Charité – Universitätsmedizin Berlin (Autor:in)
  • Kai-Martin Thoms - , Universitätsmedizin Göttingen (Autor:in)
  • Selma Ugurel - , Universitätsklinikum Essen (Autor:in)
  • Jochen Utikal - , Universitätsmedizin Mannheim (Autor:in)
  • Michael Weichenthal - , Universitätsklinikum Schleswig-Holstein Campus Kiel (Autor:in)
  • Beatrice Schuler-Thurner - , Friedrich-Alexander-Universität Erlangen-Nürnberg (Autor:in)
  • Carola Berking - , Friedrich-Alexander-Universität Erlangen-Nürnberg (Autor:in)
  • Markus V Heppt - , Friedrich-Alexander-Universität Erlangen-Nürnberg (Autor:in)

Abstract

Metastases of uveal melanoma (UM) spread predominantly to the liver. Due to low response rates to systemic therapies, liver-directed therapies (LDT) are commonly used for tumor control. The impact of LDT on the response to systemic treatment is unknown. A total of 182 patients with metastatic UM treated with immune checkpoint blockade (ICB) were included in this analysis. Patients were recruited from prospective skin cancer centers and the German national skin cancer registry (ADOReg) of the German Dermatologic Cooperative Oncology Group (DeCOG). Two cohorts were compared: patients with LDT (cohort A, n = 78) versus those without LDT (cohort B, n = 104). Data were analyzed for response to treatment, progression-free survival (PFS), and overall survival (OS). The median OS was significantly longer in cohort A than in cohort B (20.1 vs. 13.8 months; P = 0.0016) and a trend towards improved PFS was observed for cohort A (3.0 vs. 2.5 months; P = 0.054). The objective response rate to any ICB (16.7% vs. 3.8%, P = 0.0073) and combined ICB (14.1% vs. 4.5%, P = 0.017) was more favorable in cohort A. Our data suggest that the combination of LDT with ICB may be associated with a survival benefit and higher treatment response to ICB in patients with metastatic UM.

Details

OriginalspracheEnglisch
Seiten (von - bis)878-888
Seitenumfang11
FachzeitschriftFrontiers of medicine
Jahrgang17
Ausgabenummer5
PublikationsstatusVeröffentlicht - Okt. 2023
Peer-Review-StatusJa

Externe IDs

ORCID /0000-0003-4340-9706/work/151982835
Scopus 85164497457

Schlagworte

Schlagwörter

  • CTLA-4 Antigen, Humans, Immune Checkpoint Inhibitors/therapeutic use, Liver, Prospective Studies, Skin Neoplasms